PYXS

Pyxis Oncology, Inc.

BS score —UNSCOREDPHASE2 · mkt cap $101.2M · rev ttm $13.9M

drug hypothesis

PYX-201 to treat Advanced Solid Tumors.

moa:Antibody-drug conjugate (ADC) being studied in combination with pembrolizumab (PD-1 inhibitor) for advanced solid tumors. Specific target antigen and payload mechanism not disclosed in available data.

score breakdown

trial design0

base rate disconnect0

language red flags0

composite—

valuation analysis

market cap$101.2M

revenue ttm$13.9M

phasePHASE2

historical base rate—

disconnect ratio—

lead trialNCT06795412

meta

cik0001782223

first discovered2026-04-10

last updated2026-04-10

statusACTIVE

llm modelminimax/minimax-m2.5:free

extracted at2026-04-10

trial design

Phase 1/2, non-randomized, open-label study. Enrollment: 220 patients. Combination therapy: PYX-201 with pembrolizumab. Start date: 2025-04-15, Primary completion: 2027-12-06

primary endpoint:Number of Participants who Experience a Dose-Limiting Toxicity (DLT) (Day 1 to Day 21)

language red flags

SEC filing content is incomplete (only contains '5' - no business description or risk factors provided)
Target antigen not disclosed in trial data
Mechanism of action details insufficient - ADC platform and payload not characterized
No preclinical evidence or claimed differentiation data available from provided sources